Tandem Diabetes Care's stock surged 5.29% during intraday trading on Monday, extending its positive momentum from the previous session.
The sharp rise follows the company's report of better-than-expected quarterly financial results, which has prompted a wave of positive reactions from Wall Street analysts.
Several firms raised their price targets on the stock, including Truist Securities (to $27 from $24), Barclays (to $56 from $55), and Goldman Sachs (to $28 from $25). Furthermore, Lake Street made a significant move by upgrading Tandem Diabetes Care to Buy from Hold and dramatically raising its price target to $50 from $14.